Treatment with 10 mg/kg of a chicken/mouse chimeric anti-human GPC1 monoclonal antibody (mAb) was found to suppress tumor growth via the antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) as well as inhibition of tumor angiogenesis in a GPC1-positive TE14 human ESCC xenograft model and a patient-derived tumor xenograft (PDX) model [29]. Here, GPC1 is linked to neoplasm.